Correlation Between Candel Therapeutics and Nuvectis Pharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Candel Therapeutics and Nuvectis Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Candel Therapeutics and Nuvectis Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Candel Therapeutics and Nuvectis Pharma, you can compare the effects of market volatilities on Candel Therapeutics and Nuvectis Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Candel Therapeutics with a short position of Nuvectis Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Candel Therapeutics and Nuvectis Pharma.

Diversification Opportunities for Candel Therapeutics and Nuvectis Pharma

0.05
  Correlation Coefficient

Significant diversification

The 3 months correlation between Candel and Nuvectis is 0.05. Overlapping area represents the amount of risk that can be diversified away by holding Candel Therapeutics and Nuvectis Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Nuvectis Pharma and Candel Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Candel Therapeutics are associated (or correlated) with Nuvectis Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Nuvectis Pharma has no effect on the direction of Candel Therapeutics i.e., Candel Therapeutics and Nuvectis Pharma go up and down completely randomly.

Pair Corralation between Candel Therapeutics and Nuvectis Pharma

Given the investment horizon of 90 days Candel Therapeutics is expected to generate 2.95 times more return on investment than Nuvectis Pharma. However, Candel Therapeutics is 2.95 times more volatile than Nuvectis Pharma. It trades about 0.1 of its potential returns per unit of risk. Nuvectis Pharma is currently generating about 0.0 per unit of risk. If you would invest  657.00  in Candel Therapeutics on September 12, 2024 and sell it today you would earn a total of  694.00  from holding Candel Therapeutics or generate 105.63% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Candel Therapeutics  vs.  Nuvectis Pharma

 Performance 
       Timeline  
Candel Therapeutics 

Risk-Adjusted Performance

8 of 100

 
Weak
 
Strong
Very Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Candel Therapeutics are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite quite unsteady fundamental indicators, Candel Therapeutics disclosed solid returns over the last few months and may actually be approaching a breakup point.
Nuvectis Pharma 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Nuvectis Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable fundamental indicators, Nuvectis Pharma is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors.

Candel Therapeutics and Nuvectis Pharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Candel Therapeutics and Nuvectis Pharma

The main advantage of trading using opposite Candel Therapeutics and Nuvectis Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Candel Therapeutics position performs unexpectedly, Nuvectis Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nuvectis Pharma will offset losses from the drop in Nuvectis Pharma's long position.
The idea behind Candel Therapeutics and Nuvectis Pharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.

Other Complementary Tools

Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios